Stay updated on Idasanutlin Combo Therapy in AML Clinical Trial

Sign up to get notified when there's something new on the Idasanutlin Combo Therapy in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Idasanutlin Combo Therapy in AML Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.3%
    Check dated 2025-04-30T16:50:22.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Difference
    0.2%
    Check dated 2025-04-23T15:25:51.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The web page has removed significant content regarding a Phase Ib/II study on idasanutlin for treating acute myeloid leukemia, including detailed study descriptions and inclusion/exclusion criteria, while adding a new EudraCT number and a revision number.
    Difference
    10%
    Check dated 2025-04-16T12:34:49.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T05:38:05.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.0%
    Check dated 2025-04-01T22:41:49.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Difference
    0.1%
    Check dated 2025-03-25T13:39:24.000Z thumbnail image

Stay in the know with updates to Idasanutlin Combo Therapy in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Idasanutlin Combo Therapy in AML Clinical Trial page.